Considering Safety of Gene Therapy for Retinal Diseases
Experts continue their discussion of gene therapy, highlighting safety concerns and the need for more trials and data.
EP: 1.Impact of First-Line Therapy on Long-Term Outcomes in nAMD and DME
EP: 2.Choosing First-Line Therapy in nAMD or DME
EP: 3.When to Switch to More Efficacious Agents
EP: 4.Real-World Experiences With Faricimab
EP: 5.Real-World Experiences With Aflibercept 8mg
EP: 6.Efficacy and Durability: New Therapies vs Aflibercept 2mg
EP: 7.Perspectives on Retinal Fluid Management
EP: 8.Perspectives on Loading Dose Recommendations for New Therapies
EP: 9.Safety Considerations for New Therapies
EP: 10.The Impact of Biosimilars in Retinal Diseases
EP: 11.The Status of Gene Therapy Development for Retinal Diseases
EP: 12.Considering Safety of Gene Therapy for Retinal Diseases
EP: 13.Role of Tyrosine Kinase Inhibitors and Gene Therapy in Retinal Diseases
EP: 14.Perspectives on the Future of Retinal Disease Management
Summary
Experts continue their discussion on the potential of gene therapy; in particular, they explore the exciting prospect of developing an ocular biofactory within a patient's eye to produce a VEGF inhibitor. Diana Do, MD expresses enthusiasm for gene therapy but raises a critical point about the long-term safety concerns of these specialized delivery systems. She emphasizes the inability to “turn off” gene therapy and highlights the need to understand the implications of chronic VEGF suppression within the eye over an extended period. David Eichenbaum, MD acknowledges the importance of addressing safety concerns associated with gene therapy, including inflammation and adverse events.
This summary was AI-generated and edited for clarity.
